januari
coronaviru
diseas
spread
fast
china
mainli
southwest
asia
europ
especi
itali
found
everywher
around
world
diseas
caus
sever
acut
respiratori
syndrom
coronaviru
seventh
member
coronaviru
famili
infect
human
middl
east
respiratori
syndrom
coronaviru
mer
cov
sarscov
also
belong
classic
clinic
pictur
flulik
syndrom
mild
sever
case
case
complic
interstiti
pneumonia
variabl
degre
respiratori
failur
underli
patholog
chang
respons
respiratori
failur
characteris
two
patient
underw
lung
lobotomi
lung
adenocarcinoma
retrospect
found
posit
among
patient
consult
doctor
heart
symptom
palpit
chest
pain
rather
respiratori
problem
littl
known
possibl
relationship
cardiovascular
diseas
earli
report
patient
hospitalis
januari
jinyntan
hospit
wuhan
china
pneumonia
show
preexist
cardiovascular
diseas
present
second
report
period
time
patient
hospitalis
zhongnan
hospit
wuhan
univers
show
patient
requir
cardiolog
intens
care
among
patient
develop
arrhythmia
experienc
acut
coronari
syndrom
addit
complic
furthermor
patient
diagnos
pneumonia
due
infect
show
increas
highsensit
cardiac
troponin
level
suggest
myocardi
injuri
publish
anecdot
report
indic
presenc
myocard
cardiac
arrest
acut
heart
failur
patient
clear
whether
cardiac
condit
provok
complic
typic
patholog
higher
cardiometabol
demand
thu
unrel
viral
infect
epidemiolog
studi
conduct
flu
epidem
usa
show
influenza
relat
complic
secondari
pneumonia
may
caus
myocardi
infarct
due
inflammationinduc
destabilis
coronari
arteri
plaqu
result
multipl
mechan
tachycardia
hypoxia
increas
wall
stress
thrombophilia
releas
inflammatori
cytokin
possibl
causal
link
exclud
similar
link
myocardi
infarct
acut
heart
failur
shown
recent
epidem
sarscov
mersncov
absenc
specif
treatment
vaccin
accord
expert
readi
year
three
possibl
remedi
attempt
contain
spread
infect
drastic
like
unpopular
measur
quarantin
restrict
free
movement
specif
area
aim
get
epidem
exhaust
natur
hope
facilit
come
summer
northern
hemispher
support
treatment
respiratori
cardiolog
complic
infect
includ
admiss
intens
care
unit
icu
use
mechan
ventil
extracorpor
membran
oxygen
ecmo
propos
novel
approach
base
evid
varieti
field
expertis
could
help
find
possibl
therapi
short
report
would
like
contribut
experi
notch
signal
third
option
cov
envelop
singlestrand
positivesens
rna
virus
genom
rang
kb
rna
genom
encod
four
major
structur
protein
spike
protein
nucleocapsid
n
protein
membran
protein
envelop
e
protein
requir
produc
viral
particl
sequenc
analys
rna
variant
isol
patient
show
homolog
bat
viru
suggest
coronavirus
jump
bat
human
probabl
intermedi
host
yet
identifi
occurr
mutat
allow
infect
human
cell
spike
glycoprotein
mediat
entri
cell
follow
bind
angiotensin
convert
enzym
highli
express
cell
surfac
mani
tissu
organ
includ
lung
myocardium
relev
mainli
locat
inner
track
respiratori
system
thu
explain
differ
flu
viru
bind
upper
airway
track
might
caus
seriou
respiratori
insuffici
also
explain
common
influenza
like
somebodi
believ
differ
catalys
format
angiotensin
ang
ii
activ
compon
reninangiotensin
system
involv
blood
pressur
regul
cardioren
function
cleav
ang
ii
ang
thu
antagonis
activ
ang
ii
receptor
blocker
arb
wide
use
treat
hypertens
heart
failur
increas
level
ang
ii
indirectli
could
activ
propos
patient
receiv
arb
higher
suscept
consequ
hypertens
patient
heart
failur
switch
arb
drug
way
think
howev
support
evid
actual
caveat
express
reduc
hypertens
model
evid
increas
express
arb
lung
hypertens
treatment
arb
affect
previou
coronaviru
infect
base
evid
discuss
could
target
prevent
enter
cell
aim
lei
et
al
gener
recombin
protein
connect
extracellular
domain
human
fc
region
human
immunoglobulin
neutralis
sarscov
vitro
anoth
approach
prevent
viral
infect
could
downregul
cell
membran
relev
disintegrin
metalloproteas
metalloproteas
significantli
express
also
lung
heart
involv
shed
surfac
protein
includ
ablat
express
reduc
shed
wherea
overexpress
significantli
increas
shed
furthermor
membran
transloc
lead
reduct
myocardi
protein
level
activ
associ
increas
plasma
activ
base
data
tempt
specul
increas
level
andor
activ
enhanc
shed
increas
solubleplasma
level
could
repres
way
block
entri
cell
fig
relev
treatment
chemotherapeut
agent
strongli
activ
anim
model
colorect
cancer
furthermor
nonsmal
cell
lung
cancer
cell
line
estradiol
increas
express
level
activ
last
find
would
suggest
higher
shed
women
could
least
partial
explain
reduc
incid
women
compar
men
proteas
furin
also
requir
promot
entranc
viru
cell
furin
member
subtilisinlik
proprotein
convertas
famili
process
protein
secretori
pathway
type
membranebound
proteas
express
multipl
organ
includ
lung
differ
sarscov
present
furin
cleavag
site
subunit
glycoprotein
follow
bind
glycoprotein
furinmedi
proteolyt
cut
protein
necessari
viral
entri
cell
inhibit
express
furin
could
possibl
approach
prevent
infect
fig
b
relev
context
nanomolar
concentr
peptid
design
furin
cleavag
sequenc
avian
influenza
viru
provid
protect
infect
sever
furindepend
pathogen
furin
intertwin
notch
evolutionarili
conserv
system
commun
adjac
cell
thu
target
notch
could
repres
altern
approach
inhibit
furin
upregul
fig
interest
recent
studi
investig
physic
associ
fig
sever
acut
respiratori
entri
cell
mediat
bind
viral
spike
glycoprotein
angiotensin
convert
enzym
cell
follow
proteolyt
cut
site
glycoprotein
host
proteas
furin
level
plasma
membran
regul
promot
shed
protein
notch
signal
posit
regul
furin
neg
regul
transcript
thu
inhibitor
gsi
prevent
notch
activ
may
repres
strategi
interfer
viru
entri
cell
reduc
furin
increas
shed
antagomir
could
repres
altern
approach
upregul
b
notch
precursor
cleav
furin
golgi
apparatu
lead
heterodim
plasma
membran
consist
notch
extracellular
domain
necd
notch
transmembran
tm
contain
notch
intracellular
domain
nicd
bind
ligand
notch
cleav
adam
disintegrin
metalloproteas
complex
result
nicd
transloc
nucleu
interact
transcript
factor
csl
transcript
coactiv
maml
mastermindlik
regul
transcript
notch
target
gene
furin
human
protein
identifi
potenti
cellular
protein
could
target
prevent
viral
infect
approach
imposs
identifi
host
protein
crucial
viral
infect
interact
directli
viral
protein
case
furin
thu
hypothesisdriven
studi
base
knowledg
molecular
detail
viruscel
interact
still
crucial
identif
therapeut
target
treat
notch
signal
pathway
play
major
role
control
cell
fate
develop
postnat
life
grow
evid
show
notch
signal
involv
maintain
homeostasi
cardiovascular
system
could
repres
novel
target
reduc
atherosclerosi
progress
remodel
follow
myocardi
infarct
human
four
receptor
activ
bind
ligand
deltalik
ligand
dll
surfac
adjac
cell
notch
precursor
first
cleav
furin
golgi
apparatu
found
heterodim
cell
membran
follow
ligand
bind
notch
first
cleav
cell
membran
thu
enabl
final
cleavag
releas
activ
notch
intracellular
domain
migrat
nucleu
regul
transcript
target
gene
fig
furin
transcript
induc
inhibit
notch
signal
could
use
reduc
furin
level
interfer
viral
entri
cell
sinc
notch
dysregul
featur
major
cancer
notch
inhibitor
target
avail
test
manag
gastrointestin
toxic
sever
clinic
trial
cancer
patient
favor
respons
far
obtain
limit
number
patient
indic
crucial
develop
new
strategi
identifi
respond
notch
inhibitionbas
cancer
therapi
enhanc
furin
activ
activ
suggest
control
nevertheless
studi
abdomin
aorta
show
express
downregul
inhibitor
gsi
dapt
n
n
lalanyl
sphenylglycin
tbutyl
ester
sinc
gsi
differ
specif
toward
isoform
notch
exist
compound
could
test
investig
effect
possibl
shed
interest
downregul
target
signal
vascular
smooth
muscl
cell
would
interest
investig
whether
antagomir
would
increas
activ
fig
among
propos
mechan
myocardi
lung
injuri
caus
cytokin
storm
trigger
imbalanc
respons
type
type
helper
th
cell
notch
pathway
play
major
role
differenti
activ
innat
adapt
immun
cell
signal
import
induc
macrophag
polaris
experi
vitro
vivo
shown
inhibit
notch
gsi
antibodi
lead
dampen
inflamm
macrophag
directli
bind
interleukin
il
promot
respons
interferon
ifn
posit
regul
product
import
underlin
turn
increas
express
notch
ligand
thu
amplifi
notch
signal
establish
posit
feedback
loop
promot
product
th
cell
notch
signal
trigger
ligand
promot
product
inflammatori
cytokin
wherea
suppress
activ
fig
multicentr
randomis
control
trial
test
monoclon
antibodi
receptor
tocilizumab
roch
patient
pneumonia
elev
conduct
china
promis
result
base
result
phase
ii
clinic
trial
test
efficaci
tocilizumab
italian
patient
pneumonia
approv
italian
medicin
agenc
http
wwwagenz
iafar
macogoviten
phase
iii
clinic
trial
enrol
patient
global
announc
us
http
wwwroch
commedia
relea
addit
strategi
attempt
reduc
cytokin
storm
cytosorb
extracorpor
cytokin
adsorb
accord
manufactur
patient
sever
treat
cytosorb
china
itali
germani
http
cyto
orbthera
pycomencovid
howev
data
effect
approach
yet
avail
predictor
mortal
patient
howev
sever
affect
patient
moder
increas
pgml
compar
typic
level
cytokin
releas
syndrom
pgml
sepsi
may
explain
seriou
vasopleg
shock
observ
nevertheless
cytokin
storm
patient
characteris
hyperinn
immun
respons
also
activ
th
cellmedi
immun
scenario
idea
combin
notch
inhibitor
dampen
cytokin
storm
captiv
fig
howev
must
also
consid
notch
inhibit
could
interfer
immun
respons
viral
infect
ito
et
al
found
mice
infect
influenza
viru
macrophag
increas
notch
ligand
express
mice
inhibit
notch
pathway
use
antibodi
gsi
intranas
administr
result
increas
mortal
defect
viral
clearanc
decreas
product
lung
notch
signal
also
modul
immun
respons
follow
respiratori
syncyti
viru
rsv
infect
note
report
rsv
infect
caus
increas
bronchial
epitheli
cell
cocultur
cell
promot
differenti
convers
reduct
express
sirna
abrog
effect
promot
increas
differenti
basi
suggest
differenti
may
caus
rsvinduc
airway
hyperrespons
basi
studi
could
hypothesis
may
prefer
target
specif
compon
notch
signal
rather
inhibit
notch
gsi
relev
solubl
shown
effici
inhibit
neointima
format
balloon
injuri
decreas
smooth
muscl
cell
prolifer
migrat
inhibit
notch
signal
preclin
studi
shown
notch
inhibit
use
treatment
atherosclerosi
also
inflammationbas
condit
graftversushost
diseas
chronic
obstruct
pulmonari
diseas
copd
arthriti
import
point
notch
inhibit
becom
realiti
clinic
manag
patient
address
issu
could
aris
upon
chronic
exposur
notch
inhibitor
like
requir
mani
patholog
toxic
relat
multipl
cellular
target
gsi
due
promiscu
activ
alter
immun
system
activ
stem
cell
compart
notch
play
pivot
role
potenti
oncogen
treatment
given
tumour
suppressor
role
notch
tissu
like
skin
observ
alzheim
patient
treat
gsi
inhibit
format
amyloid
peptid
possibl
approach
avoid
system
toxic
could
deliveri
gsi
inhibitor
directli
lung
use
nanoparticl
notch
cooper
activ
immun
system
perpetu
cytokin
storm
macrophag
signal
promot
product
inflammatori
cytokin
among
turn
increas
express
notch
ligand
thu
amplifi
notch
signal
establish
feedback
loop
promot
product
cell
notch
signal
trigger
ligand
promot
inflammatori
cytokin
contrari
ligand
dampen
activ
tocilizumab
expect
block
cytokin
storm
prevent
tissu
damag
notch
inhibit
block
ligand
may
help
interrupt
posit
feedback
loop
fuel
cytokin
storm
macrophag
cell
base
data
conclud
even
hold
great
promis
notch
inhibit
block
cytokin
storm
patient
still
feasibl
target
receptor
deplet
cytokin
mean
repres
approach
avail
time
relationship
notch
virus
well
document
replic
virus
human
papilloma
viru
simian
viru
highjack
cell
machineri
includ
notch
signal
caus
cancer
therefor
propos
dysregul
notch
signal
could
provid
diagnost
therapeut
tool
virusassoci
cancer
uncov
new
aspect
relationship
might
abl
target
notch
also
fight
heart
lung
diseas
caus
directli
infect
cytokin
storm
respons
viru
conflict
interest
author
declar
conflict
interest
